Invenra will collaborate with Merck, a pharmaceutical company, to discover fully human therapeutic antibodies against an unnamed target of interest to Merck, the company announced recently.

“We are excited to be working with this first-rate team in Merck,” Invenra CEO Dr. Roland Green said in a statement. “Invenra’s ability to test antibodies for a functional phenotype early in the screening process combined with Merck’s established role as a leader in this field will advance the science regarding difficult to address targets.”

Financial terms were not disclosed.

Requests to Invenra for additional information were not returned.